Hirano, Mitsuhito
Imai, Yoichi
Kaito, Yuta
Murayama, Takahiko
Sato, Kota
Ishida, Tadao
Yamamoto, Junichi
Ito, Takumi
Futami, Muneyoshi
Ri, Masaki
Yasui, Hiroshi
Denda, Tamami
Tanaka, Yukihisa
Ota, Yasunori
Nojima, Masanori
Kamikubo, Yasuhiko
Gotoh, Noriko
Iida, Shinsuke
Handa, Hiroshi
Tojo, Arinobu
Funding for this research was provided by:
Janssen Pharmaceuticals
Bristol-Myers Squibb
Okinaka Memorial Institute for Medical Research
Japan Society for the Promotion of Science (1 7 K 0 9 9 1 6, 2 0 K 0 8 7 2 6)
Takeda Pharmaceutical Company
AbbVie
MSD K.K.
Article History
Received: 6 December 2020
Accepted: 14 March 2021
First Online: 23 March 2021
Declarations
:
: Animal experimentation protocols were approved by the Animal Experiment Committee at the Institute of Medical Science of the University of Tokyo (H2–04). This project was approved by the Institutional Review Board at the Institute of Medical Science of the University of Tokyo (30–72-A0222). Written informed consent was obtained from participants prior to inclusion in the study.
: Not applicable.
: YI received honoraria from Celgene/Bristol-Myers Squibb and Janssen as well as research funding from Janssen, Celgene/Bristol-Myers Squibb, Okinaka Memorial Institute for Medical Research, and JSPS KAKENHI (Grant Numbers 1 7 K 0 9 9 1 6 and 2 0 K 0 8 7 2 6). TI received honoraria from Ono, Takeda, Celgene/Bristol-Myers Squibb, Janssen. MR received research funding from Celgene/Bristol-Myers Squibb. SI has previously received honoraria from Takeda, Ono, Celgene/Bristol-Myers Squibb, Janssen, Sanofi, Daichi Sankyo, and received research funding from Takeda, Janssen, Abbvie, Celgene/Bristol-Myers Squibb, MSD, as well as endowments from Takeda, Ono, Chugai, Kyowa Kirin, Sanofi. All other authors declare no competing interests.